Lantheus Holdings (LNTH) Net Equity Issued and Repurchased (2014 - 2025)
Lantheus Holdings (LNTH) posted quarterly Net Equity Issued and Repurchased of $2.0 million for Q1 2025, up 8.78% year-over-year from $1.8 million in Q1 2024, and up 21.88% quarter-over-quarter from $1.6 million in Q3 2024.
Lantheus Holdings (LNTH) Net Equity Issued and Repurchased (2014 - 2025) Analysis & Trends
Lantheus Holdings (LNTH) has reported Net Equity Issued and Repurchased for 11 consecutive years, with $2.0 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Net Equity Issued and Repurchased rose 8.78% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $3.6 million (changed 0.0% YoY), while the FY2024 annual figure was $3.4 million, up 78.48% from the prior year.
- Net Equity Issued and Repurchased advanced to $2.0 million in Q1 2025 per LNTH's latest filing, from $1.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $2.0 million in Q1 2025 and bottomed at -$1000.0 in Q4 2021.
- Historically, Net Equity Issued and Repurchased has averaged $950800.0 across 5 years, with a median of $869000.0 in 2022.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased fell 7.92% — and 2024, when it soared 93.94%.
- Lantheus Holdings' Net Equity Issued and Repurchased stood at -$1000.0 in 2021, then jumped by 79900.0% to $798000.0 in 2022, then grew by 24.44% to $993000.0 in 2023, then surged by 63.85% to $1.6 million in 2024, then grew by 21.88% to $2.0 million in 2025.
- Business Quant data shows LNTH's Net Equity Issued and Repurchased at $2.0 million in Q1 2025, $1.6 million in Q3 2024, and $1.8 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.98 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Sep 30, 2023 | 993,000.00 |
| Sep 30, 2023 | 993,000.00 |
| Mar 31, 2023 | 940,000.00 |
| Mar 31, 2023 | 940,000.00 |
| Sep 30, 2022 | 798,000.00 |
| Sep 30, 2022 | 798,000.00 |
| Mar 31, 2022 | 577,000.00 |
| Mar 31, 2022 | 577,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | 431,000.00 |
| Sep 30, 2021 | 431,000.00 |
| Mar 31, 2021 | 337,000.00 |
| Mar 31, 2021 | 337,000.00 |